Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
British Journal of Haematology · 2025-01 · 206 (1) · 152-158
DOI: 10.1111/bjh.19827 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 15.10.2024. Verfasst von Yu-Han Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chin…. Hauptthemen laut MEDLINE: Pyrazines, Castleman Disease, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences (ClFMS), Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Idiopathic multicentric Castleman disease (iMCD) is a rare and heterogeneous lymphoproliferative disorder that lacks standardised treatment options for patients with refractory or relapsed (r/r) disease. Blocking Bruton's tyrosine kinase (BTK) has emerged as a promising therapeutic approach for iMCD without depleting B cells. This single‐centre, retrospective study enrolled 10 patients with r/r iMCD who were treated with orelabrutinib, a novel, next‐generation BTK inhibitor. The median age at orelabrutinib initiation was 48 (range: 31–58) years. The overall response rate was 70% (7/10 patients, 95% CI: 34.8–93.3), with 20% ( n = 2) achieving complete response and 50% ( n = 5) achieving partial response. The median time to response was 9.8 (range: 5.9–20.5) months. Patients in the non‐responder group also demonstrated a continuous improvement in haemoglobin (91–105 g/L) and albumin (32–38 g/L) levels at month 12 of treatment despite not fulfilling response criteria. No grade 3 or higher adverse events occurred during the median time to the next treatment of 29.0 (range: 15.0–36.2) months. No patient mortality was recorded during the median follow‐up duration of 32.8 (range: 15.0–36.9) months. In conclusion, orelabrutinib is a safe and effective regimen for r/r iMCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yu-Han Gao, Si-Yuan Li, Yue Dang, Ming-Hui Duan, Lu Zhang, Jian Li
Förderung
- CAMS Innovation Fund for Medical Sciences (ClFMS)
- Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Gao, Y. H., Li, S. Y., Dang, Y., Duan, M. H., Zhang, L., & Li, J. (2025). Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study. British Journal of Haematology, 206(1), 152-158. https://doi.org/10.1111/bjh.19827
Vancouver
Gao YH, Li SY, Dang Y, Duan MH, Zhang L, Li J. Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study. British Journal of Haematology. 2025;206(1):152-158. doi:10.1111/bjh.19827
BibTeX
@article{Gao2025,
author = {Gao, Yu-Han and Li, Si-Yuan and Dang, Yue and Duan, Ming-Hui and Zhang, Lu and Li, Jian},
title = {Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {1},
pages = {152--158},
doi = {10.1111/bjh.19827}
}
EUVIMED